<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362843</url>
  </required_header>
  <id_info>
    <org_study_id>060214</org_study_id>
    <secondary_id>06-M-0214</secondary_id>
    <nct_id>NCT00362843</nct_id>
  </id_info>
  <brief_title>Protein Synthesis in the Brain of Patients With Fragile X Syndrome</brief_title>
  <official_title>PET Measurement of Regional Rates of Cerebral Protein Synthesis in Subjects With Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Biosynthesis of proteins is essential for growth and continued maintenance of the entire
      neuron including axons, dendrites, and synaptic terminals, and it is clearly one of the
      important biochemical processes underlying adaptive changes in the nervous system. Studies in
      experimental animals with the quantitative autoradiographic L [1 (14)C]leucine method have
      demonstrated a number of the physiological and pathological conditions in which changes in
      regional rates of cerebral protein synthesis (rCPS) occur.

      We have recently developed the first fully quantitative method for determining rCPS with
      positron emission tomography (PET). The PET method was adapted from the autoradiographic L [1
      (14)C]leucine method; it uses L [1 (11)C]leucine as the PET tracer, dynamic scanning, and a
      kinetic modeling approach for quantification. This method was validated in nonhuman primates
      by comparison of PET measurements with those based on established biochemical and
      autoradiographic techniques.

      The objective of the present study is to examine the degree to which changes in rCPS in human
      subjects can be quantified with the L [1 (11)C]leucine PET method. We propose three studies
      to be carried out sequentially. In Part I we will establish the L-[1-(11)C]leucine PET method
      in human subjects. In Part II we will measure rCPS in normal control subjects in two states:
      awake and under deep sedation/general anesthesia with propofol. A difference in rCPS between
      these two states may indicate that we can detect activity-dependent protein synthesis with
      the PET method. In Part III we will study subjects with fragile X syndrome. This patient
      group was chosen since the affected gene in fragile X syndrome codes for a protein that is
      thought to be a negative regulator of message translation. Thus an effect on protein
      synthesis may be very close to the underlying genetic abnormality in fragile X syndrome.
      Regionally selective increases in rCPS have been found in studies in a mouse model of this
      disease.

      The present study will establish the sensitivity of the L [1 (11)C]leucine PET method to
      detect changes in rCPS in human subjects. A quantitative and sensitive method to measure rCPS
      with PET will augment the tools available for investigating the brain and its regional
      adaptive responses. Ultimately the method may have widespread applications, not only for the
      study of normal development and plasticity but also in clinical medicine, e.g., in the
      investigation of disorders of brain development, recovery from brain injury, and
      neurodegenerative diseases.

      SPECIFIC AIMS

        1. &lt;TAB&gt;Establish the L-[1-(11)C]leucine PET method for measurement of rCPS in human
           subjects. Evaluate the optimal scan time and the variability of the measurement in an
           individual.

        2. &lt;TAB&gt;Determine the effect of deep sedation with propofol on rCPS in normal human
           subjects. We will use the [1-(11)C]leucine PET method to evaluate lambda, i.e., the
           fraction of the precursor pool for protein synthesis that is derived from arterial
           plasma, and rCPS in the same subjects under awake and deep sedation conditions.

           I)&lt;TAB&gt;Hypothesis 1a. Deep sedation with propofol has effects on rCPS.

           II)&lt;TAB&gt;Hypothesis 1b. Deep sedation with propofol has effects on values of lambda.

        3. &lt;TAB&gt;Assess the sensitivity of the [1-(11)C]leucine PET method to detect differences in
           rCPS in subjects with fragile X syndrome.

      I)&lt;TAB&gt;Hypothesis 3a. There are regionally selective changes in rCPS in subjects with fragile
      X syndrome compared with age-matched healthy controls. Regions affected include hippocampus,
      thalamus, hypothalamus, amygdala, and frontal and parietal cortex.

      II)&lt;TAB&gt;Hypothesis 3b. In centrum semiovale, cerebellum, striatum and occipital and temporal
      cortex rCPS are unchanged in subjects with fragile X syndrome compared with age-matched
      healthy controls.

      III)&lt;TAB&gt;Hypothesis 3c. Values of lambda in the brain as a whole and in the regions examined
      are unchanged in subjects with fragile X syndrome compared with age-matched healthy controls.

      IV) Hypothesis 3d. The average rate of protein synthesis in the brain as a whole is unchanged
      in subjects with fragile X syndrome compared with age-matched healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biosynthesis of proteins is essential for growth and continued maintenance of the entire
      neuron including axons, dendrites, and synaptic terminals, and it is clearly one of the
      important biochemical processes underlying adaptive changes in the nervous system. Studies in
      experimental animals with the quantitative autoradiographic L-[1-(14)C]leucine method have
      demonstrated a number of the physiological and pathological conditions in which changes in
      regional rates of cerebral protein synthesis (rCPS) occur.

      We have recently developed the first fully quantitative method for determining rCPS with
      positron emission tomography (PET). The PET method was adapted from the autoradiographic
      L-[1-(14)C]leucine method; it uses L-[1-(11)C]leucine as the PET tracer, dynamic scanning,
      and a kinetic modeling approach for quantification. This method was validated in nonhuman
      primates by comparison of PET measurements with those based on established biochemical and
      autoradiographic techniques.

      The objective of the present study is to examine the degree to which changes in rCPS in human
      subjects can be quantified with the L-[1-(11)C]leucine PET method. We propose three studies
      to be carried out sequentially. In Part I we will establish the L-[1-(11)C]leucine PET method
      in human subjects. In Part II we will measure rCPS in normal control subjects in two states:
      awake and under deep sedation/general anesthesia with propofol. A difference in rCPS between
      these two states may indicate that we can detect activity-dependent protein synthesis with
      the PET method. In Part III we will study subjects with fragile X syndrome. This patient
      group was chosen since the affected gene in fragile X syndrome codes for a protein that is
      thought to be a negative regulator of message translation. Thus an effect on protein
      synthesis may be very close to the underlying genetic abnormality in fragile X syndrome.
      Regionally selective increases in rCPS have been found in studies in a mouse model of this
      disease.

      The present study will establish the sensitivity of the L-[1-(11)C]leucine PET method to
      detect changes in rCPS in human subjects. A quantitative and sensitive method to measure rCPS
      with PET will augment the tools available for investigating the brain and its regional
      adaptive responses. Ultimately the method may have widespread applications, not only for the
      study of normal development and plasticity but also in clinical medicine, e.g., in the
      investigation of disorders of brain development, recovery from brain injury, and
      neurodegenerative diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 8, 2006</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Regional rates of cerebral protein synthesis</measure>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fragile X Syndrome</condition>
  <condition>Healthy Volunteers</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Fragile X subjects:

        Male subjects, 18-24 years of age, with diagnosis of fragile X syndrome will be considered.
        Diagnosis will be confirmed by molecular genetic testing. Subjects with CGG repeat
        sequences greater than 200 and methylation of FMR1 will be included.

        Control:

        Male subjects, 18-24 years of age will be considered.

        EXCLUSION CRITERIA:

        Fragile X subjects:

        Fragile X subjects with a high level of repeat size or methylation mosaicism will be
        excluded. Fragile X subjects on psychotropic medications will be excluded from the study.
        Fragile X subjects who have received radiation doses for research purposes exceeding 4 rem
        (whole body effective dose) in the previous 12 months will be excluded. Fragile X subjects
        in whom MRI is contraindicated will be excluded. Subjects with metal objects in their
        bodies, such as pacemakers, aneurysm clips (metal clips on the wall of a large artery),
        metallic prostheses, cochlear implants, or shrapnel fragments will be excluded from the
        study. Welders and metal workers at risk for eye injury because of unsuspected tiny metal
        fragments there will also be excluded. Subjects in whom sedation is contraindicated will be
        excluded. Fragile X subjects on medications that interfere with blood coagulation will be
        excluded (see Appendix 1). In addition, fragile X subjects with respiratory illnesses or
        cardiovascular diseases will be excluded as there might be increased risk of complications
        with sedation/anesthesia.

        Control:

        Subjects with premutation alleles, i.e., repeat length between 55 and 200 will be excluded.
        Subjects with IQ less than 90 or subnormal language skills will be excluded. Subjects on
        psychotropic medication will be excluded from the study. Subjects who have received
        radiation doses for research purposes exceeding 3.5 rem (whole body effective dose) in the
        previous 12 months and subjects for whom MRI is contraindicated will be excluded. Subjects
        in whom sedation is contraindicated will be excluded from Part II. Subjects on medications
        that interfere with blood coagulation will be excluded (see Appendix 1). Subjects with any
        previous history of psychiatric or neurological disease, as assessed by the Structured
        Clinical Interview for DSM-IV (SCID), will be excluded. In addition, subjects with
        respiratory illnesses or cardiovascular diseases will be excluded from Part II as there
        might be increased risk of complications with sedation/anesthesia. Subjects positive for
        HIV will be excluded from the study. Subjects with positive results on the urine drug
        screen will be excluded.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn B Smith, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael S Rosenheck</last_name>
    <phone>(301) 451-8995</phone>
    <email>michael.rosenheck@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolyn B Smith, Ph.D.</last_name>
    <phone>(301) 451-8995</phone>
    <email>beebe@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2006-M-0214.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Chen L, Toth M. Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience. 2001;103(4):1043-50.</citation>
    <PMID>11301211</PMID>
  </reference>
  <reference>
    <citation>Coenen HH, Kling P, St√∂cklin G. Cerebral metabolism of L-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med. 1989 Aug;30(8):1367-72.</citation>
    <PMID>2787848</PMID>
  </reference>
  <reference>
    <citation>Davis HP, Squire LR. Protein synthesis and memory: a review. Psychol Bull. 1984 Nov;96(3):518-59.</citation>
    <PMID>6096908</PMID>
  </reference>
  <verification_date>April 10, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2006</study_first_submitted>
  <study_first_submitted_qc>August 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2006</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>11C-Leucine</keyword>
  <keyword>Positron Emission Tomography (PET)</keyword>
  <keyword>Cerebral Protein Synthesis</keyword>
  <keyword>Propofol</keyword>
  <keyword>Fragile X</keyword>
  <keyword>Fragile X Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fragile X Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

